

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>SVLSF VI, LLC</b>  (Last) (First) (Middle) <b>ONE BOSTON PLACE, SUITE 3900</b> <b>201 WASHINGTON STREET</b>  (Street) <b>BOSTON MA 02108</b>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>AVROBIO, Inc. [ AVRO ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <b>06/25/2018</b>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/25/2018		C		2,207,843	A	(1)	2,207,843	I	See Footnote(2)
Common Stock	06/25/2018		C		75,591	A	(3)	75,591	I	See Footnote(4)
Common Stock	06/25/2018		C		437,611	A	(5)	2,645,454	I	See Footnote(2)
Common Stock	06/25/2018		C		14,982	A	(6)	90,573	I	See Footnote(4)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(3)	06/25/2018		C		9,122,809		(7)	(7)	Common Stock	2,207,843	\$0.00	0	I	See footnote(2)
Series A Preferred Stock	(3)	06/25/2018		C		312,341		(7)	(7)	Common Stock	75,591	\$0.00	0	I	See footnote(4)
Series B Preferred Stock	(3)	06/25/2018		C		1,808,211		(7)	(7)	Common Stock	437,611	\$0.00	0	I	See footnote(2)
Series B Preferred Stock	(3)	06/25/2018		C		61,908		(7)	(7)	Common Stock	14,982	\$0.00	0	I	See footnote(4)

1. Name and Address of Reporting Person\*  
**SVLSF VI, LLC**  
 (Last) (First) (Middle)  
**ONE BOSTON PLACE, SUITE 3900**  
**201 WASHINGTON STREET**  
 (Street)  
**BOSTON MA 02108**  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
**SV Life Sciences Fund VI, L.P.**  
 (Last) (First) (Middle)  
**ONE BOSTON PLACE, SUITE 3900**

201 WASHINGTON STREET

(Street)  
BOSTON MA 02108

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[SV Life Sciences Fund VI Strategic Partners, L.P.](#)

(Last) (First) (Middle)

ONE BOSTON PLACE, SUITE 3900  
201 WASHINGTON STREET

(Street)  
BOSTON MA 02108

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[SV Life Sciences Fund VI \(GP\), L.P.](#)

(Last) (First) (Middle)

ONE BOSTON PLACE, SUITE 3900  
201 WASHINGTON STREET

(Street)  
BOSTON MA 02108

(City) (State) (Zip)

**Explanation of Responses:**

1. Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI, L.P. ("SV Life LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
2. The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P. ("SV Fund VI GP") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP, except to the extent of any pecuniary interest therein.
3. Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Life SP LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
4. The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein.
5. Represents the total number of shares of Common Stock received by SV Life LP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
6. Represents the total number of shares of Common Stock received by SV Life SP LP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
7. All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

**Remarks:**

[SV Life Sciences Fund VI, L.P.](#),  
[By: SV Life Sciences Fund VI](#)  
[\(GP\), L.P., Its: sole General](#)  
[Partner, By: SVLSF VI, LLC, 06/25/2018](#)  
[ItsL sole General Partner, By:](#)  
[Brent M. Faduski, Officer, /s/](#)  
[Brent M. Faduski](#)

[SV Life Sciences Fund VI](#)  
[Strategic Partners, L.P., By: SV](#)  
[Life Sciences Fund VI \(GP\),](#)  
[L.P., Its: sole General Partner,](#)  
[By: SVLSF VI, LLC, Its: sole 06/25/2018](#)  
[General Partner, By: Brent M.](#)  
[Faduski, Officer, /s/ Brent M.](#)  
[Faduski](#)

[SV Life Sciences Fund VI \(GP\),](#)  
[L.P., By: SVLSF VI, LLC, Its:](#)  
[sole General Partner, By: Brent 06/25/2018](#)  
[M. Faduski, Officer, /s/ Brent M.](#)  
[Faduski](#)

[SVLSF VI, LLC, By: Brent M.](#)  
[Faduski, Officer, /s/ Brent M. 06/25/2018](#)  
[Faduski](#)

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.